Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of SX-682 (CXCR1/2 Inhibitor) Combined With Proton Craniospinal Irradiation for Patients With Leptomeningeal Disease

NCT07814352 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07814352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07814352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of SX-682 (CXCR1/2 Inhibitor) Combined With Proton Craniospinal Irradiation for Patients With Leptomeningeal Disease
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 4, 2026
Completion date
September 30, 2029
Enrollment
40 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal disease (lmd)